Abstract: The catalyst thin layer consists of electronically conductive catalyst nano-particles embedded in a polymeric matrix. The ratio number of catalyst atoms/total number of atoms in the catalyst layer is comprised between 40% and 90%, more preferably between 50% and 60%.

Abstract: This invention pertains to gaseous analytes sensor devices comprising organic thin film transistor and, in particular, sensors able to perform the enantiomeric discrimination of gaseous analytes.

Abstract: The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

Abstract: Nephrogenic diabetes insipidus is treated with statins.

Abstract: A system measures the strain of an object. The system includes a laser source for generating an output radiation, a strainable optical fiber having first and second facets, and means for calculating a measure of a strain of the optical fiber. The first facet is coupled to the laser source to receive the output radiation and transmit a guided radiation over the optical fiber towards the second facet. The second facet is adapted to receive the guided radiation and to reflect a corresponding reflected radiation towards the first facet. The laser source is a self-mixing type adapted to receive at least part of the reflected radiation and to mix the output radiation with the received radiation. The calculating means calculate the measure of the strain of the optical fiber based on a self-mixing effect in the laser source that is caused by the linear displacement of the second section.

Abstract: The present invention relates to a renal carcinoma cell line capable of activating the immune system in an antigen-specific manner. According to a further aspect, the invention also includes derivatives of the cell line that maintain said activation capacity. The invention also comprises a method for targeting and activating immune system cells against cells of clear cell renal carcinoma. Said method comprises the co-incubation of isolated immune system cells (dendritic cells, CD4+, CD8+ lymphocytes etc.) with cells of the RCC BA85#21 line in accordance with the invention in a suitable culture medium, for a time sufficient to obtain antigen specific cells.

Abstract: The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

Abstract: The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

Abstract: The catalyst thin layer consists of electronically conductive catalyst nano-particles embedded in a polymeric matrix. The ratio number of catalyst atoms/total number of atoms in the catalyst layer is comprised between 40% and 90%, more preferably between 50% and 60%.

Abstract: Isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

Abstract: This invention pertains to gaseous analytes sensor devices comprising organic thin film transistor and, in particular sensors able to perform the enantiomeric discrimination of gaseous analytes. The organic thin films are characterized by comprising a compound of formula (I).

Abstract: A system measures the strain of an object. The system includes a laser source for generating an output radiation, a strainable optical fiber having first and second facets, and means for calculating a measure of a strain of the optical fiber. The first facet is coupled to the laser source for receiving the output radiation and for transmitting therefrom a guided radiation over the optical fiber towards the second facet. The second facet is adapted to receive the guided radiation and to reflect a corresponding reflected radiation towards the first facet. The laser source is a self-mixing type adapted to receive at least part of the reflected radiation and to mix the output radiation with the received radiation. The calculating means calculate the measure of the strain of the optical fiber through the linear displacement of the second section measured by the self-mixing effect in the laser source.

Abstract: A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto.

Abstract: A series of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides was prepared and their affinity for serotonin 5-HT7, 5-HT1A, and 5-HT2A receptors was measured using in vitro binding assays. In relation to 5-HT7 receptor affinity, receptor binding studies indicated that: (i) the optimal alkyl chain length was five methylenes; (ii) an unsubstituted 1,2,3,4-tetrahydronaphthalenyl nucleus was selected for further substitutions; and (iii) the substitution pattern of the aryl ring linked to the piperazine ring played a significant role. Several compound with high affinity for 5-HT7 receptors were identified.

Abstract: Object of the present invention is the use of bone marrow stromal cells, in particular autologous stromal cells, for the treatment of injuries to tendons and/or ligaments in mammals, in particular horses and especially racehorses. A further object of the present invention is a process for the treatment of injuries to tendons and/or ligaments in mammals that includes the delivery of bone marrow stromal cells, which are preferably autologous, into the lesions and a composition of bone marrow stromal cells, which are preferably autologous, for the treatment of the injured tendons and/or ligaments of a mammal, in particular a horse.

Abstract: A process for synthesizing complexes of platinum(II) with iminoethers having the formula: [PtIIX2(L)(L′)], where X is a monoanionic ligand, L is an iminoether ligand and L′ is an amine group or, exclusively for the case of cyclic iminoethers, a second iminoether ligand. The platinum(II) complexes according to the present invention are suitable for the production of medical remedies having a broad antitumoral spectrum. The complexes of platinum(II) with iminoethers according to the invention are furthermore suitable as agents for modifying nucleotide bases into antisense and/or antigene oligonucleotides.